$170,000 of SAGE THERAPEUTICS lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Mental Health Innovation at large substances - Cares Act. Telehealth and controlled substance prescribing habits for serious mental illness. Extension of Public Health Emergency Act for telehealth. Senate drug pricing reforms under Medicare Part D. TRIPS Waiver. Fixes to the Inflation Reduction Act of 2022 (P.L.117-169). Mental Health Care - PPD screening guidelines in Momnibus bills (H.R.3305/S.1606). PPD Screening.
Telehealth Medicare physician reimbursement. P.L.117-169 - Inflation Reduction Act of 2022 and potential fixes to the IRA. Maternal mental health legislation, like Momnibus (H.R.3305/S.1606).
FDA reforms via appropriations."
You can find more data on corporate lobbying on Quiver Quantitative.
SAGE Hedge Fund Activity
We have seen 77 institutional investors add shares of SAGE stock to their portfolio, and 82 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 1,265,376 shares (+541.5%) to their portfolio in Q3 2024
- JPMORGAN CHASE & CO removed 1,049,152 shares (-87.4%) from their portfolio in Q3 2024
- ACADIAN ASSET MANAGEMENT LLC added 946,254 shares (+161476.8%) to their portfolio in Q3 2024
- VANGUARD GROUP INC removed 655,872 shares (-10.2%) from their portfolio in Q3 2024
- MORGAN STANLEY removed 581,902 shares (-41.8%) from their portfolio in Q3 2024
- INVESCO LTD. removed 573,223 shares (-86.7%) from their portfolio in Q3 2024
- FMR LLC removed 552,248 shares (-9.5%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
